Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2OGZ5)

• Drug Name: Morin Drug Info
• Synonyms: morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5281670
  ChEBI ID: CHEBI:75092
  CAS Number: CAS 480-16-0
  TTD Drug ID: DM2OGZ5
  VARIDT Drug ID: DR00652

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[5]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[7]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[7]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[8]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[9]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[10]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[11]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[12]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[12]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[12]

Drug(s) Targeting Fatty acid synthase (FASN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[13]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[14]
TVB-2640	DMP30SA	Non-alcoholic fatty liver disease	DB92	Phase 2	[15]
FAS1	DMAX2EW	Fungal infection	1F29-1F2F	Preclinical	[16]
FSA2	DMLNRCI	Fungal infection	1F29-1F2F	Preclinical	[16]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Plasmodium Enoyl-ACP reductase (Malaria fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[17]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[18]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[19]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[19]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
Thiolactomycin	DMBAWDG	Malaria	1F40-1F45	Investigative	[17]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[3]
Diazaborines	DM5UFZX	Discovery agent	N.A.	Investigative	[20]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[3]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[5]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[3]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[3]
NADPH	DM75Q34	Discovery agent	N.A.	Investigative	[21]

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated estrogens	DMLT0E1	Menopause symptom	GA30.0	Approved	[22]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[23]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[24]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[25]
Premarin/Pravachol	DMLSOB7	Hyperlipidaemia	5C80	Phase 3	[26]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[27]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[28]
AUS-131	DMZMSQJ	Hot flushes	GA30	Phase 2	[29]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[30]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[31]

Drug(s) Targeting Urate anion exchanger 1 (URAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lesinurad	DMUR64T	Hyperuricaemia	5C55.Y	Approved	[32]
URC102	DMY89BN	Gout	FA25	Phase 2	[33]
RDEA-684	DMNWYHD	Gout	FA25	Phase 2	[32]
RDEA3170	DM1TKG4	Hyperuricaemia	5C55.Y	Phase 2	[34]
Sulfonamide derivative 11	DMJBR86	N. A.	N. A.	Patented	[35]
Cycloalkyl acid derivative 1	DMXMGSP	N. A.	N. A.	Patented	[35]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1	DMHYIAV	N. A.	N. A.	Patented	[35]
Tihoacetate derivative 1	DM6QHO0	N. A.	N. A.	Patented	[35]
Cycloalkyl acid derivative 2	DM09LY3	N. A.	N. A.	Patented	[35]
Succinamide derivative 1	DMTXDSG	N. A.	N. A.	Patented	[35]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[2]
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[3]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[2]
Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)	TTHPFTS	Q965D7_PLAFA	Inhibitor	[3]
Plasmodium Enoyl-ACP reductase (Malaria fabI)	TTNX2CS	Q965D5_PLAFA	Inhibitor	[3]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)	TTBE4IR	Q965D6_PLAFA	Inhibitor	[3]
Urate anion exchanger 1 (URAT1)	TTA592U	S22AC_HUMAN	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 411).
• [2] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [3] Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
• [4] Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) express... Drug Metab Dispos. 2007 Jun;35(6):981-6.
• [5] 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
• [6] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Prelude Therapeutics.
• [9] Clinical pipeline report, company report or official report of AbbVie.
• [10] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
• [11] Clinical pipeline report, company report or official report of Amgen.
• [12] Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
• [13] Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
• [14] Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
• [15] Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
• [16] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [17] Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
• [18] Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
• [19] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [20] Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
• [21] Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
• [22] Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [24] Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
• [25] Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
• [26] Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
• [27] MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
• [28] Company report (Axcentua)
• [29] S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
• [30] Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
• [32] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
• [33] Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
• [34] The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
• [35] Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.